Quantcast

Latest Antibody Stories

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-03-10 23:24:13

Xtalks presents an exciting live webinar on Wednesday, March 26, 2014 at 11:00 EDT (15:00 GMT). Join keynote speaker Dr. Dhaval Shah, Assistant Professor at the Department of Pharmaceutical Sciences, University at Buffalo, for a one-hour presentation to learn Using PK/PD modeling for Antibody Drug Conjugate Translation. Toronto, Canada (PRWEB) March 10, 2014 Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the...

2014-03-10 08:29:22

- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA)....

2014-03-07 08:21:14

DUBLIN, Mar. 07, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cl5vpz/antibody_target ) has announced the addition of the "Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription" subscription to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 2,400 project entries for...

2014-03-06 23:04:31

Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans. Somerset, NJ (PRWEB) March 06, 2014 Catalent Pharma Solutions, the global...

2014-03-06 12:26:44

DUBLIN, Mar. 06, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/njgf7d/research_report ) has announced the addition of the "Concise Analysis of the International and China Monoclonal Antibody Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale of monoclonal antibody was only over...

2014-03-05 08:29:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" [http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from...

2014-03-05 04:22:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific ) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" [http://www.researchandmarkets.com/research/885sfr/bispecific ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Antibody based therapeutics are the fastest growing segment of the drugs and...

2014-02-27 18:33:27

By re-engineering a tiny chain of amino acids in one type of dengue virus, Ralph Baric and Aravinda de Silva discover a new path toward solving the dengue vaccine dilemma. The research has the potential to transform vaccine development for other diseases, including SARS and HIV. Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related